Cover Image
市場調查報告書

細菌性肺炎:開發中產品分析

Bacterial Pneumonia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 265421
出版日期 內容資訊 英文 212 Pages
訂單完成後即時交付
價格
Back to Top
細菌性肺炎:開發中產品分析 Bacterial Pneumonia - Pipeline Review, H2 2016
出版日期: 2016年12月28日 內容資訊: 英文 212 Pages
簡介

所謂細菌性肺炎是指細菌侵入肺葉,引起肺泡發炎,讓肺臟充滿膿、體液及細胞殘骸這樣的感染症。一旦發病便會損及人體體內代謝氧及二氧化碳的機能。致病危險因子包含年齡,及長期間使用免疫抑制劑,長期間服用皮質類固醇劑的慢性阻塞性肺病(COPD)患者、吸煙者等。主要的症狀有伴隨攙有黃·綠色或血痰的咳嗽、頭痛、肌肉痛、呼吸困難或迫促、沒精神、意識不清等。

本報告提供全球各國治療細菌性肺炎所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

細菌性肺炎概要

治療藥的開發

  • 細菌性肺炎開發中產品:概要
  • 細菌性肺炎開發中產品:比較分析

各企業開發中的的細菌性肺炎治療藥

各大學/研究機關研究中的細菌性肺炎治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

細菌性肺炎治療藥:開發中的產品一覽(各企業)

細菌性肺炎治療藥:研究中的產品一覽(各大學/研究機關)

細菌性肺炎開發治療藥的企業

  • Abera Bioscience AB
  • Actelion Ltd
  • Alvogen Korea Co., Ltd.
  • Aridis Pharmaceuticals LLC
  • Arsanis Biosciences GmbH
  • AstraZeneca Plc
  • Beijing Minhai Biotechnology Co., Ltd
  • ContraFect Corporation
  • 第一三共
  • Double Bond Pharmaceutical International AB
  • Emergent BioSolutions Inc.
  • Eurocine Vaccines AB
  • FluGen, Inc.
  • GlaxoSmithKline Plc
  • Humabs BioMed SA
  • ImmunoBiology Limited
  • Indian Immunologicals Limited
  • Integrated BioTherapeutics, Inc.
  • 杏林藥業
  • Lascco SA
  • LG Life Science LTD.
  • Liquidia Technologies, Inc.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Mucosis B.V.
  • Noxxon Pharma AG
  • Panacea Biotec Limited
  • Prometheon Pharma, LLC
  • Sanofi Pasteur SA
  • Serum Institute of India Limited
  • SK Chemicals Co., Ltd.
  • 大日本住友製藥
  • Valneva SE
  • Vaxxilon AG
  • Virometix AG
  • Walvax Biotechnology Co., Ltd.
  • Wellstat Vaccines, LLC
  • Wockhardt Limited

細菌性肺炎:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

細菌性肺炎治療藥:暫停的計劃

細菌性肺炎治療藥:開發中止的產品

細菌性肺炎相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8851IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Pneumonia - Pipeline Review, H2 2016, provides an overview of the Bacterial Pneumonia (Infectious Disease) pipeline landscape.

Bacterial pneumonia is an infection in one or both lungs. The bacteria cause the lung's air sacs (alveoli) to become inflamed and engorged with pus, fluid, and cellular debris. This often impairs the body's ability to exchange oxygen and carbon dioxide. Predisposing factors are age, long-term users of immunosuppressant drugs, chronic obstructive pulmonary disease (COPD) patients who use inhaled corticosteroids for lengthy periods and smokers. Symptoms include cough with yellow, green, or blood-tinged mucus, headache, muscle pain, breathlessness or rapid breathing, lethargy and confusion.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacterial Pneumonia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bacterial Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 8, 13, 2, 30, 12 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 9 and 6 molecules, respectively.

Bacterial Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Pneumonia (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Bacterial Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bacterial Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bacterial Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Pneumonia (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bacterial Pneumonia (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bacterial Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Bacterial Pneumonia Overview
  • Therapeutics Development
  • Bacterial Pneumonia - Therapeutics under Development by Companies
  • Bacterial Pneumonia - Therapeutics under Investigation by Universities/Institutes
  • Bacterial Pneumonia - Pipeline Products Glance
  • Bacterial Pneumonia - Products under Development by Companies
  • Bacterial Pneumonia - Products under Investigation by Universities/Institutes
  • Bacterial Pneumonia - Companies Involved in Therapeutics Development
  • Bacterial Pneumonia - Therapeutics Assessment
  • Drug Profiles
  • Bacterial Pneumonia - Dormant Projects
  • Bacterial Pneumonia - Discontinued Products
  • Bacterial Pneumonia - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Bacterial Pneumonia, H2 2016
  • Number of Products under Development for Bacterial Pneumonia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Bacterial Pneumonia - Pipeline by Abera Bioscience AB, H2 2016
  • Bacterial Pneumonia - Pipeline by Actelion Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Affinivax Inc, H2 2016
  • Bacterial Pneumonia - Pipeline by Allergan Plc, H2 2016
  • Bacterial Pneumonia - Pipeline by Aridis Pharmaceuticals LLC, H2 2016
  • Bacterial Pneumonia - Pipeline by Arsanis Inc, H2 2016
  • Bacterial Pneumonia - Pipeline by AstraZeneca Plc, H2 2016
  • Bacterial Pneumonia - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Biken Inc, H2 2016
  • Bacterial Pneumonia - Pipeline by ContraFect Corp, H2 2016
  • Bacterial Pneumonia - Pipeline by Crestone Inc, H2 2016
  • Bacterial Pneumonia - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Double Bond Pharmaceutical International AB, H2 2016
  • Bacterial Pneumonia - Pipeline by Emergent BioSolutions Inc, H2 2016
  • Bacterial Pneumonia - Pipeline by FluGen Inc, H2 2016
  • Bacterial Pneumonia - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Bacterial Pneumonia - Pipeline by ImmunoBiology Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Indian Immunologicals Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Integrated BioTherapeutics Inc, H2 2016
  • Bacterial Pneumonia - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Lascco SA, H2 2016
  • Bacterial Pneumonia - Pipeline by LegoChem Biosciences Inc, H2 2016
  • Bacterial Pneumonia - Pipeline by LG Life Science LTD, H2 2016
  • Bacterial Pneumonia - Pipeline by Liquidia Technologies Inc, H2 2016
  • Bacterial Pneumonia - Pipeline by MedImmune LLC, H2 2016
  • Bacterial Pneumonia - Pipeline by Merck & Co Inc, H2 2016
  • Bacterial Pneumonia - Pipeline by Mucosis BV, H2 2016
  • Bacterial Pneumonia - Pipeline by Noxxon Pharma AG, H2 2016
  • Bacterial Pneumonia - Pipeline by Panacea Biotec Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Pfizer Inc, H2 2016
  • Bacterial Pneumonia - Pipeline by Polyphor Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Prometheon Pharma LLC, H2 2016
  • Bacterial Pneumonia - Pipeline by Sanofi Pasteur SA, H2 2016
  • Bacterial Pneumonia - Pipeline by Serum Institute of India Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Shionogi & Co Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by SK Chemicals Co Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Valneva SE, H2 2016
  • Bacterial Pneumonia - Pipeline by Vaxxilon AG, H2 2016
  • Bacterial Pneumonia - Pipeline by Virometix AG, H2 2016
  • Bacterial Pneumonia - Pipeline by Wellstat Vaccines LLC, H2 2016
  • Bacterial Pneumonia - Pipeline by Wockhardt Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Bacterial Pneumonia - Dormant Projects, H2 2016
  • Bacterial Pneumonia - Dormant Projects (Contd..1), H2 2016
  • Bacterial Pneumonia - Dormant Projects (Contd..2), H2 2016
  • Bacterial Pneumonia - Dormant Projects (Contd..3), H2 2016
  • Bacterial Pneumonia - Dormant Projects (Contd..4), H2 2016
  • Bacterial Pneumonia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Bacterial Pneumonia, H2 2016
  • Number of Products under Development for Bacterial Pneumonia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top